A

    Ascendis Pharma AS (ASND)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $263.04
    +15.13 (+6.10%)

    Market Cap: $16.26B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    35%(14/40)
    Avg Surprise
    -19.72%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.95
    Range$0.68 - $1.09
    3 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$1.20+25.8%
    60d ago$1.20+25.8%
    30d ago$1.25+31.9%
    7d ago$1.32+38.6%
    Current$0.95
    Revenue Consensus
    $366M
    Range$352M - $376M
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$9.77
    Range$2.04 - $14.03
    4 analysts
    Revenue Consensus
    $398M
    Range$363M - $447M
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$9.77---
    Sep 26EST
    		-$0.95---
    Jun 26
    Reported Aug 6
    		$3.29$0.78+321.79%Beat+453.8%
    Mar 26
    Reported May 7
    		$0.27$0.43-37.21%Miss+117.1%
    Dec 25
    Reported Feb 11
    		$-0.55$-0.24-129.17%Miss+14.1%
    Sep 25
    Reported Nov 12
    		$-1.00$-0.12-733.33%Miss+41.9%
    Jun 25
    Reported Aug 7
    		$-0.93$-1.42+34.51%Beat+55.9%
    Mar 25
    Reported May 1
    		$-1.58$-1.51-4.64%Miss+31.3%
    Dec 24
    Reported Feb 12
    		$-0.64$-1.17+45.30%Beat+58.4%
    Sep 24
    Reported Nov 14
    		$-1.72$-1.46-17.81%Miss+40.3%
    Jun 24
    Reported Sep 3
    		$-2.11$-1.46-44.52%Miss+2.3%
    Mar 24
    Reported May 2
    		$-2.30$-1.42-61.97%Miss-16.2%
    Dec 23
    Reported Feb 7
    		$-1.54$-1.76+12.50%Beat+58.4%
    Sep 23
    Reported Nov 7
    		$-2.88$-2.25-28.00%Miss+5.0%
    Jun 23
    Reported Sep 5
    		$-2.16$-2.59+16.60%Beat-47.9%
    Mar 23
    Reported Apr 27
    		$-1.98$-2.62+24.43%Beat+10.4%
    Dec 22
    Reported Feb 16
    		$-3.70$-2.56-44.53%Miss-97.9%
    Sep 22
    Reported Nov 2
    		$-3.03$-2.53-19.76%Miss-106.1%
    Jun 22
    Reported Aug 10
    		$-1.46$-2.25+35.11%Beat+41.6%
    Mar 22
    Reported May 11
    		$-2.21$-1.99-11.06%Miss-88.9%
    Dec 21
    Reported Mar 2
    		$-1.87$-2.34+20.09%Beat+29.2%
    Sep 21
    Reported Nov 10
    		$-1.47$-2.29+35.81%Beat+36.4%
    Jun 21
    Reported Aug 25
    		$-2.50$-2.23-12.11%Miss-26.9%
    Mar 21
    Reported May 27
    		$-1.17$-1.90+38.42%Beat+11.4%
    Dec 20
    Reported Mar 10
    		$-2.64$-1.55-70.32%Miss-39.7%
    Sep 20
    Reported Nov 11
    		$-2.31$-1.59-45.28%Miss-335.8%
    Jun 20
    Reported Aug 27
    		$-1.97$-1.44-36.81%Miss-57.6%
    Mar 20
    Reported Apr 1
    		$-1.32$-1.30-1.54%Miss-6.5%
    Dec 19
    Reported Dec 31
    		$-1.89$-1.62-16.67%Miss-119.8%
    Sep 19
    Reported Nov 18
    		$-0.53N/A+54.31%Beat+34.6%
    Jun 19
    Reported Aug 28
    		$-1.25$-1.20-4.17%Miss-127.3%
    Mar 19
    Reported Apr 3
    		$-1.24$-1.02-21.57%Miss-15.9%
    Dec 18
    Reported Dec 31
    		$-0.86$-1.14+24.56%Beat+6.5%
    Sep 18
    Reported Nov 28
    		$-0.81$-1.02+20.59%Beat+22.1%
    Jun 18
    Reported Aug 29
    		$-0.55$-0.86+36.05%Beat+41.5%
    Mar 18
    Reported May 30
    		$-1.07$-0.74-44.59%Miss-37.2%
    Dec 17
    Reported Mar 28
    		$-0.92$-0.80-15.00%Miss-37.3%
    Sep 17
    Reported Nov 16
    		$-1.04$-0.73-42.47%Miss-44.4%
    Jun 17
    Reported Aug 18
    		$-0.94$-0.74-27.03%Miss-
    Mar 17
    Reported May 23
    		$-0.78$-0.70-11.43%Miss-
    Dec 16
    Reported Mar 22
    		$-0.67$-0.62-8.06%Miss-
    Sep 16
    Reported Nov 30
    		$-0.72$-0.60-20.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio130.87EV/EBITDA71.77x
    Price/FCF46.46xFCF Yield2.15%
    Profitability
    Profit Margin70.90%Operating Margin65.00%
    ROE118.80%ROIC4.00%
    Financial Health
    Debt/Equity0.05xInterest Coverage0.36x
    Current Ratio2.99xQuick Ratio2.32x
    Trading Statistics
    Beta0.48Avg Volume516.35K
    52-Week High$282.1552-Week Low$186.05

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$253.21
    SMA 20$251.69
    SMA 50$255.51
    SMA 200$231.27
    EMA 10$253.12
    EMA 20$252.58
    EMA 50$250.33
    EMA 200$231.36

    MACD

    Line: 0.51Signal: -0.03Hist: 0.54

    ADX

    ADX: 12.9+DI: 29.3-DI: 18.0

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down24.0
    PSAR$243.77

    Bollinger Bands

    Upper Band$261.49
    Lower Band$241.90
    %B Position778%(Upper)
    Band Width1.08

    RSI (14-Day)

    Neutral
    61.0

    Momentum Oscillators

    Stoch %K51.8
    Stoch %D47.1
    Williams %R-21.0
    ROC (10d)6.3%
    Momentum15.64
    CCI (20d)145.6
    MFI (14d)48.1

    Volatility Measures

    ATR (14d)$8.15(3.1%)
    StdDev (20d)4.90
    Hist Vol33.3%(Moderate)

    Volume Flow

    VWAP$259.89
    OBV-487.3K
    AD Line6.8M
    CMF (20d)-0.005

    Volume Metrics

    Avg Vol (20d)511.0K
    Vol Ratio1.9x(High)
    VWMA (20d)$251.64

    Pivot Points

    R3$253.92
    R2$252.08
    R1$249.99
    Pivot Point$248.15
    S1$246.06
    S2$244.22
    S3$242.13

    Advanced Oscillators

    TSI2.03
    Ultimate Osc51.2
    KST-14.77

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$344.90M$250.66M$245.18M$213.63M$158.04M$100.95M$173.92M$57.83M$36.00M$95.89M$137.70M$48.03M
    Cost of Revenue$32.30M$21.62M$27.20M$22.35M$31.45M$17.52M$14.02M$11.20M$11.46M$7.57M$19.46M$7.39M
    Gross Profit$312.61M$229.03M$217.98M$191.28M$126.60M$83.44M$159.89M$46.63M$24.53M$88.33M$118.25M$40.65M
    Operating Expenses$249.17M$203.81M$208.18M$180.28M$179.55M$187.65M$159.51M$143.38M$157.79M$137.47M$154.86M$175.05M
    R&D$74.65M$57.63M$74.98M$66.88M$71.99M$86.60M$79.30M$73.54M$83.48M$70.69M$90.88M$111.44M
    SG&A$0$145.23M$135.00M$111.69M$105.71M$95.65M$78.78M$68.13M$72.30M$72.30M$63.98M$62.51M
    Operating Income$63.43M$25.22M$9.80M$11.00M$-52,951,000$-104,212,000$383,000$-96,743,000$-133,257,000$-49,145,000$-36,611,000$-134,407,000
    Interest Income$0$4.52M$4.37M$3.33M$55.06M$28.85M$14.90M$28.28M$49.05M$3.58M$60.13M$4.14M
    Interest Expense$14.41M$68.36M$61.40M$19.72M$33.02M$44.79M$56.63M$25.35M$19.62M$77.16M$68.55M$24.52M
    Income Before Tax$233.90M$-48,969,254$-26,454,575$-57,372,000$-35,007,000$-93,565,000$-37,384,000$-98,178,000$-109,151,000$-128,527,000$-81,088,000$-161,578,000
    Income Tax Expense$23.51M$-688,657,525$6.79M$3.62M$3.85M$1.06M$1.08M$1.02M$229,000$2.51M$5.79M$645,000
    Net Income$210.40M$639.69M$-33,247,273$-60,989,000$-38,855,000$-94,626,000$-38,469,000$-99,198,000$-109,380,000$-131,035,000$-86,878,000$-162,223,000
    EBITDA$68.08M$23.68M$39.72M$-53,353,000$2.32M$-44,234,000$-37,893,000$-71,129,000$-87,510,000$-46,889,000$-67,686,000$-132,316,000
    EBIT$63.43M$19.39M$34.94M$-57,372,000$-1,989,000$-48,779,000$-42,368,000$-72,831,000$-89,527,000$-51,392,354$-72,535,297$-137,196,954
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ASND

    News

    Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

    Ascendis Pharma and BioMarin Pharmaceutical Inc. have entered into a binding term sheet for a global settlement and license agreement regarding YUVIWEL® and navepegritide-related products. BioMarin will grant Ascendis a non-exclusive, worldwide, royalty-bearing license and waive certain regulatory rights, while Ascendis will make royalty payments to BioMarin based on net sales in specific regions until May 20, 2030. This agreement resolves all ongoing litigation and disputes between the companies, allowing Ascendis to continue commercializing YUVIWEL, which was recently approved in the U.S. for achondroplasia.

    Yahoo! Finance Canada•8/31/26•
    Bullish

    Ascendis to present 2-year achondroplasia trial data at ISDS

    Ascendis Pharma A/S will present two-year data from its ApproaCH Trial of once-weekly TransCon CNP in children with achondroplasia at the International Skeletal Dysplasia Society annual meeting. The presentation will cover data from the trial’s open-label extension. TransCon CNP, marketed as YUVIWEL, received FDA approval in February 2026 for treating achondroplasia and is currently under review by the European Medicines Agency.

    Investing.com India•8/26/26•
    Bullish

    Ascendis Announces Oral Presentation of Week 104 Data from

    Ascendis Pharma announced an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia at ISDS 2026. The data reinforces durable improvements in height, lower-extremity alignment, and other physical functions with a safety profile similar to placebo. TransCon CNP was approved by the U.S. FDA in February 2026 and its Marketing Authorisation Application is currently under review by the European Medicines Agency.

    GlobeNewswire•8/26/26•
    Bullish

    Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

    Ascendis Pharma A/S announced that Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia will be presented at the ISDS 2026 conference. The data, to be presented by Carlos Bacino, M.D., highlights durable improvements in height, body proportionality, and physical functioning, with a safety profile similar to placebo. TransCon CNP, approved as YUVIWEL® by the FDA in February 2026, aims to counteract overactive FGFR3 signaling in achondroplasia, a rare genetic condition affecting over 250,000 people worldwide.

    Yahoo Finance Singapore•8/25/26•
    Bullish

    Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Strong-Buy at BMO Capital Markets

    BMO Capital Markets has upgraded Ascendis Pharma A/S (NASDAQ:ASND) to a "strong-buy" rating, reflecting a generally bullish outlook from analysts with an average "Buy" rating and a target price of $300.33. The company reported quarterly revenue of $387.22 million, exceeding expectations, despite missing EPS estimates. Insider and institutional investments remain supportive, with a director purchasing additional shares and significant insider ownership.

    MarketBeat•8/20/26•
    Bullish

    Frequently Asked Questions About ASND

    Does ASND pay dividends?
    Ascendis Pharma AS (ASND) does not currently pay a regular dividend.
    What is ASND's P/E ratio?
    Ascendis Pharma AS has a price-to-earnings (P/E) ratio of 130.87.
    What is ASND's market cap?
    Ascendis Pharma AS (ASND) has a market capitalization of $16.26B with a current stock price of $263.04.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In